Exploring anti-malarial potential of FDA approved drugs: an in silico approach.

ABSTRACT:

Background

The critically important issue on emergence of drug-resistant malarial parasites is compounded by cross resistance, where resistance to one drug confers resistance to other chemically similar drugs or those that share mode of action. This aspect requires discovery of new anti-malarial compounds or formulation of new combination therapy. The current study attempts to contribute towards accelerating anti-malarial drug development efforts, by exploring the potential of existing FDA-approved drugs to target proteins of Plasmodium falciparum.

Methods

Using comparative sequence and structure analyses, FDA-approved drugs, originally developed against other pathogens, were identified as potential repurpose-able candidates against P. falciparum. The rationale behind the un

SUBMITTER: Ramakrishnan G 

PROVIDER: S-EPMC5516367 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature